+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a long-term observational study to understand the natural history, symptoms, and progression of fucosidosis, a rare disease without any approved treatments. This study aims to collect detailed information from individuals diagnosed with fucosidosis to better characterize the disease and inform future research and treatment development. The study is sponsored by JCR Pharmaceuticals Co., Ltd. and includes both retrospective and prospective components. The study has two parts Part A involves collecting past medical data from up to 57 participants, while Part B includes ongoing prospective data collection from up to 31 participants, many of whom may have participated in Part A. No experimental treatments are given participants receive only their usual medical care during the study. Participants will be observed over time to evaluate disease progression, with data collected from medical records and regular follow-up visits. The primary goal is to assess how fucosidosis develops in untreated individuals over up to four years. Information collected includes symptoms, treatment history, and clinical assessments to help researchers understand the disease course and support future study design. Participation may last several years depending on individual involvement in prospective data collection.

All AgesAll Genders
16 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
P

Actively Recruiting

This research aims to evaluate the long-term safety of luspatercept in participants who have previously taken part in other luspatercept clinical trials for conditions such as Myelodysplastic Syndromes MDS, Beta-thalassemia, and Myeloproliferative Neoplasm-associated Myelofibrosis. It is a Phase 3b, open-label, single-arm rollover study designed to continue monitoring participants who tolerated previous luspatercept treatment and may benefit from ongoing therapy, as well as those in post-treatment follow-up phases. Participants transitioning from prior luspatercept studies will enter a Transition Phase defined by an enrollment visit. Those continuing treatment will receive luspatercept injections subcutaneously at the same dose and schedule as their parent trial, administered by study staff at clinical sites. The study includes a Treatment Phase for ongoing luspatercept administration and a Follow-up Phase comprising a 42-day safety follow-up after the last dose and a long-term post-treatment follow-up phase lasting at least 5 years to monitor overall survival and progression to malignancies. Throughout the study, participants will be regularly assessed for adverse events, progression to high-risk MDS or AML, and development of other malignancies or treatment-related masses. Safety parameters are evaluated during the 42-day follow-up, while long-term survival and disease progression are monitored every six months for at least five years. The study will conclude when all participants have completed five years of combined treatment and follow-up.

Age: 18Years +All GendersPhase 3
143 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
S

Actively Recruiting

Pediatric patients undergoing spine surgery to correct scoliosis face significant risks related to blood loss during the procedure. This research aims to identify factors before and during surgery that increase the chance of needing transfusions of donor red blood cells. The study also evaluates how using a device called Cell Saver, which recycles the patients own blood during surgery, may reduce the need for these transfusions. The study looks at a group of children under 18 who had posterior instrumented spinal fusion surgery for scoliosis between April 2023 and March 2026. Researchers retrospectively analyze these cases to find risk factors for donor blood transfusions and assess the impact of reinfusing blood collected by the Cell Saver device during surgery. The surgical correction is done under general anesthesia using standard techniques. Participants data from the start of surgery until three days after are reviewed to measure how many required donor red blood cell transfusions and how much blood was saved by the Cell Saver device. The primary outcome is the proportion of patients needing donor blood within this period. Secondary outcomes include the rate of blood conservation achieved during surgery and total transfusion volume. This observational study is led by Mehdi Trifa and is expected to complete by the end of 2026.

Age: 0 - 17YearsAll Genders
1 location
C

Actively Recruiting

This research aims to compare three different blood clot prevention treatments in adults who are having their first total knee replacement surgery. The study focuses on how these treatments affect blood flow in the veins of the lower limbs after surgery. It also evaluates other important health factors like rehabilitation progress, bleeding, and complications such as venous thromboembolism and cardiovascular issues during the recovery period. Participants will be randomly assigned to one of three treatment groups receiving apixaban twice daily, rivaroxaban once daily, or a weight-adjusted dose of enoxaparin once daily. All participants initially receive enoxaparin six hours after surgery, followed by their assigned treatment starting 24 hours after surgery, continuing for 14 days. Blood flow will be assessed with Doppler ultrasound at baseline and on Days 7, 15, 21, and 28 after surgery, with the examiner unaware of treatment assignments. During the study, participants will undergo several evaluations including Doppler ultrasound measurements of blood flow in specific leg veins, assessments of joint movement, pain, immobilization, and any postoperative complications. The main outcome measured is the peak speed of blood flow in the common femoral vein over 28 days. Safety and recovery will be closely monitored, and the total follow-up lasts 28 days after surgery.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Shoulder tendinopathy is a common condition causing pain and limiting daily activities due to damage or overuse of the rotator cuff tendons. Researchers are comparing two injection treatments for this condition corticosteroid injections, which reduce inflammation and provide quick pain relief but may have short-term effects, and Platelet-Rich Plasma PRP injections, made from the patients own blood, which may promote longer-term healing. This trial involves adult patients diagnosed with simple shoulder tendinopathy confirmed by clinical examination and imaging. The study randomly assigns 60 adult participants to receive either a single corticosteroid injection or a single PRP injection into the affected shoulder tendon. Corticosteroid injections aim to quickly reduce pain and inflammation, while PRP injections focus on promoting tissue healing and longer-term recovery. Both injections are given under sterile conditions by trained physicians. Patients will be monitored for changes in pain and shoulder function at one week and three months after the injection. Participants will undergo evaluations before the injection and at follow-up visits one week and three months later. Pain levels will be measured using a visual analog scale VAS, and shoulder function will be assessed with the Disabilities of the Arm, Shoulder and Hand DASH score and the Shoulder Pain and Disability Index SPADI. These assessments will help determine which treatment provides better pain relief and functional improvement over time. The study is conducted at the Rheumatology Department of Charles Nicolle Hospital in Tunis, Tunisia, with a total participation duration of about three months post-injection.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are observing the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent in patients with multivessel coronary artery disease who need coronary revascularization using drug-eluting stents. This study includes a broad group of patients reflecting everyday clinical practice, including those with chronic coronary artery disease and acute coronary syndromes such as STEMI and NSTEMI. It aims to gather real-world data on this stents use in multiple vessel treatments. The study involves the use of the Supraflex Cruz Sirolimus-eluting Coronary Stent System, which is a biodegradable polymer-coated cobalt-chromium stent releasing sirolimus. All treated vessels will exclusively receive this stent during the procedure. Patients are followed according to routine clinical practice, with scheduled follow-ups either by phone or in person at 30 days, 6 months, and 12 months after the initial procedure. The study also plans subgroup analyses based on clinical presentation and lesion characteristics. Participants will undergo standard clinical evaluations and follow-up visits over one year to monitor outcomes such as Target Lesion Failure, mortality, myocardial infarction, revascularization, stent thrombosis, and target vessel failure. Follow-ups are designed to align with regular care schedules and include telephonic or clinical assessments. The total participation time for each patient is approximately 12 months, allowing researchers to collect comprehensive data on stent performance and patient safety in a real-world setting.

Age: 18Years - 99YearsAll Genders
2 locations
E

Actively Recruiting

Researchers are evaluating whether delayed umbilical cord clamping improves early health outcomes compared with immediate clamping in preterm infants born between 32 and 37 weeks. Preterm babies are at increased risk of complications, and the timing of cord clamping may affect blood volume, iron levels, and neonatal adaptation after birth. This study is conducted in a tertiary maternity center in Tunisia to better understand these effects. Participants are assigned to one of two groups delayed cord clamping, where the umbilical cord is clamped at least 30 seconds after birth allowing continued placental blood flow or immediate cord clamping, where the cord is clamped within seconds after birth without delay. Both procedures are done right after delivery with standard neonatal stabilization and care provided accordingly. During the study, newborns will be monitored for early outcomes such as respiratory status, need for resuscitation, hemoglobin levels, and neonatal morbidities including anemia, necrotizing enterocolitis, and intraventricular hemorrhage. Researchers will track neonatal mortality within 7 days or until hospital discharge, length of NICU stay, and other health indicators. Participation lasts through early neonatal hospitalization and follow-up assessments may occur up to several months after birth.

Age: 0Days +All GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are evaluating two methods for setting positive end-expiratory pressure PEEP during general anesthesia in adults undergoing upper abdominal digestive surgery who are at moderate or high risk for postoperative lung complications. The trial aims to compare whether adjusting PEEP based on driving pressure can reduce the number of participants experiencing one or more postoperative pulmonary complications within the first 7 days after surgery, compared to using a fixed standard PEEP level. This randomized clinical trial involves adults with an American Society of Anesthesiologists ASA physical status of I, II, or stable III and an ARISCAT score of 26 or higher. Participants will be randomly assigned to one of two groups. In the individualized PEEP group, participants receive a lung recruitment maneuver followed by a decremental PEEP trial to find the PEEP level with the lowest driving pressure, maintaining adequate oxygenation and stable blood pressure during surgery. The standard PEEP group will receive lung-protective ventilation with PEEP fixed at 5 cmH2O throughout surgery. Other ventilatory and perioperative care components are standardized between groups, and participants and outcome assessors remain unaware of treatment allocation. During the study, participants will be monitored from the end of surgery through postoperative day 7 for lung complications. Assessments include measurements of ventilation parameters during surgery and postoperative outcomes such as length of hospital stay, intensive care admissions, and vital signs. The main outcome is the presence of postoperative pulmonary complications within 7 days after surgery. Safety and other clinical data will be collected up to 30 days post-surgery to understand the interventions effects on recovery and hospital use.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 25

1